Evidence supporting the use of: Propionyl-L-Carnitine
For the health condition: Angina

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Propionyl-L-carnitine (PLC) is a derivative of L-carnitine, a compound involved in mitochondrial energy metabolism. There is scientific evidence supporting its use as an adjunct treatment for angina pectoris, particularly in patients with chronic stable angina. Several randomized controlled trials and meta-analyses have evaluated the efficacy of PLC in improving symptoms of angina. For example, a 2003 meta-analysis (Am J Cardiol, 2003) found that L-carnitine and its derivatives, including PLC, were associated with reduced frequency and severity of angina attacks and improved exercise tolerance in patients with chronic stable angina. The proposed mechanism is improved myocardial energy metabolism and enhanced peripheral vasodilation, potentially leading to greater oxygen delivery to heart tissue.

However, the overall quality of evidence is moderate. Many studies had relatively small sample sizes, short durations, or methodological limitations. PLC is generally well-tolerated, but its use is not as widely established or recommended as standard anti-anginal therapies such as beta-blockers or nitrates. It is primarily used as an adjunct, not a replacement for conventional treatments.

In summary, there is scientific validation for the use of propionyl-L-carnitine in angina, supported by clinical studies, although the strength of the evidence is moderate (rated 3/5). It may be considered for patients who are refractory to standard therapies or as a complementary option, but more large-scale, high-quality trials are needed.

More about Propionyl-L-Carnitine
More about Angina

Products containing Propionyl-L-Carnitine

We currently have no products on Vitabase that contain this ingredient.